Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2147169 | 0.88 | ENPP2 (0.40) | RAPGEF4AHRALDH1A1TSHRCYP3A4 | |
| SCHEMBL3729974 | 0.83 | TSHR (0.48) | AHRALDH1A1TSHRHSD17B10CYP3A4 | |
| SCHEMBL13494614 | 0.80 | ALDH1A1 (0.38) | RAPGEF4AHRALDH1A1TSHRHSD17B10 | |
| SCHEMBL29955565 | 0.80 | ALDH1A1 (0.38) | RAPGEF4AHRALDH1A1TSHRHSD17B10 | |
| SCHEMBL30905965 | 0.78 | NPC1 (0.31) | RAPGEF4SMN1; SMN2 | |
| SCHEMBL1425551 | 0.74 | TSHR (0.52) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL29957125 | 0.74 | TSHR (0.52) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL12781052 | 0.73 | CA2 (0.35) | RAPGEF4ALDH1A1TSHRERN1HTT | |
| SCHEMBL24425038 | 0.72 | ALDH1A1 (0.34) | ALDH1A1TSHRHSD17B10CYP3A4RECQL | |
| SCHEMBL13744875 | 0.72 | ERN1 (0.44) | ALDH1A1TSHRHSD17B10CYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | RAPGEF4 4713/4885AHR 3414/4885ALDH1A1 3259/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | RAPGEF4 4713/4885AHR 3414/4885ALDH1A1 3259/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | RAPGEF4 4713/4885AHR 3414/4885ALDH1A1 3259/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | RAPGEF4 4713/4885AHR 3414/4885ALDH1A1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.